Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 28

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1
Chunk 28
---
 to finance our operations internally. In connection with an
evaluation conducted by our management during the preparation of the financial statements included in this Annual Report, management concluded
that there were conditions and events which raised substantial doubt as to the Company’s ability to continue as a going concern
within twelve months after the date of the issuance of the financial statements included in this Annual Report.

The
uncertainty regarding our ability to continue as a going concern could materially adversely affect our share price and our ability to
service our indebtedness, raise new capital or enter into commercial transactions. To address these matters, we may take actions that
materially and adversely affect our business, including significant reductions in research, development, administrative and commercial
activities, reduction of our employee base, and ultimately curtailing or ceasing operations, any of which could materially adversely affect
our business, financial condition, results of operations and share price. In addition, doubts about our ability to continue as a going
concern could impact our relationships with partners, vendors and other third parties and our ability to obtain, maintain or renew contracts
with them, or negatively impact our negotiating leverage with such parties, which could have a material adverse effect on our business,
financial condition and results of operations. Furthermore, any loss of key personnel, employee attrition or material erosion of employee
morale arising out of doubts about our ability to operate as a going concern could have a material adverse effect on our ability to effectively
conduct our business and could impair our ability to execute our strategy and implement our business objectives, thereby having a material
adverse effect on our business, financial condition and results of operations.

Risks Related to Our Business Operations

Delays, interruptions or the cessation of
production by our third-party suppliers of important materials or delays in qualifying new materials, has and may continue to prevent
or delay our ability to manufacture our Hemopurifier.

Most of the raw materials
used in the process for manufacturing our Hemopurifier are available from more than one supplier. However, there are materials within
the manufacturing and production process that come from single suppliers. We do not have written contracts with all of our single source
suppliers, and at any time they could stop supplying our orders. FDA review of a new supplier is required if these materials become unavailable
from our current suppliers. In the recent past, we experienced an interruption in the manufacturing of our Hemopurifier as we sought to
transition to a new supplier of galanthus nivalis agglutinin